Valensi P, Perret G, Vassy R, Uzzan B, Nicolas P, Attali J R
Service d'Endocrinologie, Hôpital Avicenne, Bobigny, France.
Fundam Clin Pharmacol. 1989;3(1):59-66. doi: 10.1111/j.1472-8206.1989.tb00031.x.
Nifedipine (10 mg tid) or placebo was administered in a randomized double-blind trial for 1 wk to 2 groups of 10 mildly hypertensive euthyroid patients. Hormonal concentrations (thyrotropin [TSH], prolactin [PRL], thyroxin, triiodothyronine, and reverse triiodothyronine) before and during a TRH test were assessed in the 2 groups before (D0) and after (D7) each treatment. Parameters of the TRH test were determined (peak values, area under the curve [AUC], release [Kr], and elimination [Ke] rate constants) and their D7:D0 ratios were compared in the 2 groups. The TSH (peak values and Kr) and PRL (peak values and AUC) responses to TRH were significantly decreased in the nifedipine group compared to the placebo group. Neither basal nor TRH-stimulated thyroid hormone levels were modified. These results confirm experimental data but seem to be clinically irrelevant.
在一项随机双盲试验中，给两组各10名轻度高血压甲状腺功能正常的患者服用硝苯地平（10毫克，每日三次）或安慰剂，为期1周。在每次治疗前（D0）和治疗后（D7），对两组患者在促甲状腺激素释放激素（TRH）试验前及试验期间的激素浓度（促甲状腺激素[TSH]、催乳素[PRL]、甲状腺素、三碘甲状腺原氨酸和反三碘甲状腺原氨酸）进行评估。确定TRH试验的参数（峰值、曲线下面积[AUC]、释放[Kr]和消除[Ke]速率常数），并比较两组的D7:D0比值。与安慰剂组相比，硝苯地平组对TRH的TSH反应（峰值和Kr）和PRL反应（峰值和AUC）显著降低。基础甲状腺激素水平和TRH刺激后的甲状腺激素水平均未改变。这些结果证实了实验数据，但似乎在临床上并无关联。
